Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Frontline BioVentures

Founders Lianyong Chen

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 12
Average round size
info
The average size of a deal this fund participated in
$83M
Portfolio companies 9
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.25
Exits 3
Key employees 1

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Manufacturing
  • Pharmaceutical
Summary

The venture was found in Asia in China. The main department of described VC is located in the Shanghai.

Among the most popular fund investment industries, there are Software, Medical. Among the most popular portfolio startups of the fund, we may highlight Innovent Biologics, Ultivue, TenNor Therapeutics. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China.

The fund is constantly included in less than 2 deals per year. This Frontline BioVentures works on 4 percentage points more the average amount of lead investments comparing to the other organizations. Considering the real fund results, this VC is 30 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2015. The increased amount of exits for fund were in 2018.

The standard case for the fund is to invest in rounds with 4 partakers. Despite the Frontline BioVentures, startups are often financed by F-Prime Capital, Lilly Asia Ventures, Hansjoerg Wyss. The meaningful sponsors for the fund in investment in the same round are Yonghua Capital, WuXi Healthcare Ventures, Temasek Holdings. In the next rounds fund is usually obtained by Temasek Holdings, Taikang Life Insurance, Legend Capital.

The current fund was established by Lianyong Chen. We also calculated 1 valuable employee in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Frontline BioVentures:
Typical Co-investors
Frontline BioVentures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Frontline BioVentures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ADV England, London, United Kingdom
AlphaBlock Capital -
Ampal-American Israel Herzliya, Israel, Tel Aviv
Business Angels Switzerland (BAS) Switzerland, Zürich, Zurich
Cocos Blockchain Expedition Beijing, Beijing, China
DeltaPoint Capital Management New York, Rochester, United States
Dubai Future Accelerators Dubai, United Arab Emirates
eonCapital Centennial, Colorado, United States
GHO Capital England, London, United Kingdom
Great Pacific Securities -
Homebrew California, San Francisco, United States
Inlign Wealth -
InOne Media China, Guangdong, Panyu
Leo Partners Investment Seoul, Seoul-t'ukpyolsi, South Korea
Natural Gas Partners Irving, Texas, United States
Panasonic Japan, Kadoma, Osaka Prefecture
Primecap Management California, Pasadena, United States
Zheke Huifu Chuang Tou China, Hangzhou, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Ultivue

Biopharma
Biotechnology
Pharmaceutical
$20M23 Jan 2018 Cambridge, Massachusetts, United States

Yidebang

Health Care
Software
$9M09 Nov 2017 Beijing

TenNor Therapeutics

Biotechnology
Medical
Therapeutics
$25M19 Sep 2016 New Jersey, United States

Hua Medicine

Biotechnology
Health Care
Life Science
Medical
Pharmaceutical
$50M21 Apr 2016 Shanghai, China

Coherent Biopharma

$8M01 Feb 2016 Suzhou, Jiangsu, China

xInnovent Biologics

Biopharma
Biotechnology
Drug Discovery
Manufacturing
Pharmaceuticals
$115M22 Jan 2015 Gusu District, Jiangsu, China

Hua Medicine

Biotechnology
Health Care
Life Science
Medical
Pharmaceutical
$25M08 Jan 2015 China, Shanghai

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Frontline BioVentures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 12
Average round size 83M
Peak activity year 2014
Lead investments 4
Follow on index 0.25
Exits 3
Group Appearance index 0.83

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Ultivue

Biopharma
Biotechnology
Pharmaceutical
$20M23 Jan 2018 Cambridge, Massachusetts, United States

Yidebang

Health Care
Software
$9M09 Nov 2017 Beijing

TenNor Therapeutics

Biotechnology
Medical
Therapeutics
$25M19 Sep 2016 New Jersey, United States

Hua Medicine

Biotechnology
Health Care
Life Science
Medical
Pharmaceutical
$50M21 Apr 2016 Shanghai, China

Coherent Biopharma

$8M01 Feb 2016 Suzhou, Jiangsu, China

xInnovent Biologics

Biopharma
Biotechnology
Drug Discovery
Manufacturing
Pharmaceuticals
$115M22 Jan 2015 Gusu District, Jiangsu, China

Hua Medicine

Biotechnology
Health Care
Life Science
Medical
Pharmaceutical
$25M08 Jan 2015 China, Shanghai
Crunchbase icon

Content report

The following text will be sent to our editors: